Assessment of the influence of different factors on the risk of the development of a new coronavirus infection in patients with contrast induced acute kidney injury

Cover Page

Cite item

Full Text

Abstract

Aim. The main aim of our study was to assess the role of risk factors in patients with previous contrast induced acute kidney injury (CI-AKI) on a probability of a development of the new coronavirus infection.

Materials and methods. Our study includes 65 patients with the history of CI-AKI after coronary angiography from 2013 to 2017 years; 10 of them had a new coronavirus infection, which had developed before November 2020. CI-AKI was defined as an increase of 25% or more, or an absolute increase of 0.5 mg/dl or more in serum creatinine from baseline value, assessed at 48 hours following the administration of the contrast. The primary endpoint was the development of a new coronavirus infection.

Results. We found statistically significant difference in the prevalence of the allergic reaction to iodine (р=0.0178) between non-COVID and COVID-patients group. Also, there were statistically significant differences in the secondary endpoints: renal replacement therapy (р=0.0178) and repeated percutaneous coronary intervention in the last year (р=0.0112) were more common among patients with coronavirus. The difference in the prevalence of arterial hypertension was near to statistical significance (р=0.0882).

Conclusion. COVID-patients with CI-AKI had more allergic reactions to iodine than non-COVID patients. The trend of more common arterial hypertension between COVID-patients was found in our research. There were not any statistical significant differences in other risk factors. There were statistically significant difference in the secondary endpoints such as repeated percutaneous coronary intervention and renal replacement therapy. Other endpoints didn’t show a statistically significant difference.

About the authors

Georgy O. Isaev

Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: isago1804@gmail.com
ORCID iD: 0000-0002-4871-8797

клин. ординатор каф. факультетской терапии №1

Russian Federation, Moscow

Olga Iu. Mironova

Sechenov First Moscow State Medical University (Sechenov University)

Email: isago1804@gmail.com
ORCID iD: 0000-0002-5820-1759

канд. мед. наук, доц. каф. факультетской терапии №1

Russian Federation, Moscow

Viktor V. Fomin

Sechenov First Moscow State Medical University (Sechenov University)

Email: isago1804@gmail.com
ORCID iD: 0000-0002-2682-4417

д-р мед. наук, проф., зав. каф. факультетской терапии №1

Russian Federation, Moscow

References

  1. Волгина Г.В., Козловская Н.Л., Щекочихин Д.Ю. Клинические рекомендации по профилактике, диагностике и лечению контраст-индуцированной нефропатии. Научное общество нефрологов России. 2013. Режим доступа: http://endovascular-society.ru/download/guidelines_ 2/CIN_rus.pdf [Volgina GV, Kozlovskaya NL, Schekochikhin DYu. Clinical practice guidelines for the prevention, diagnosis and treatment of contrast-induced nephropathy. Scientific Society of Nephrologists of Russia. 2013. Available at: http://endovascular-society.ru/download/guidelines_ 2/CIN_rus.pdf (in Russian)].
  2. Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol. 2010;5(1):4-9. doi: 10.2215/CJN.05200709
  3. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930-6. doi: 10.1053/ajkd.2002.32766
  4. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA. 1996;275:1489-94. doi: 10.1001/jama.1996.03530430033035
  5. Harjai KJ, Raizada A, Shenoy C, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol. 2008;101(6):812-9. doi: 10.1016/j.amjcard.2007.10.051
  6. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):3. Available at: https://linkinghub.elsevier.com/retrieve/pii/S2157171615310406. Accessed: 01.03.2012
  7. Алиментарные анемии. Доклад научной группы ВОЗ. Женева, 1970 [Alimentary anemias. Report of the WHO scientific group. Geneva, 1970 (in Russian)].
  8. Williams B, Mancia G, De Backer G, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2018;25(6):1105-87. doi: 10.1093/eurheartj/ehy339
  9. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-200m. doi: 10.1093/eurheartj/ehw128
  10. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. New Engl J Med. 2019;380(22):2146-55. doi: 10.1056/nejmra1805256
  11. Weisbord SD, Mor MK, Resnick AL, et al. Prevention, incidence, and outcomes of contrast-induced acute kidney injury. Arch Intern Med. 2008;168:1325-32. doi: 10.1001/archinte.168.12.1325
  12. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. doi: 10.1001/jama.2020.2648
  13. Zhao L, Zhang Y, Yang X, Liu X. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019. Allergy. 2020. doi: 10.1111/all.14455
  14. Ng JH, Hirsch JS, Wanchoo R, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98(6):1530-9. doi: 10.1016/j.kint.2020.07.030
  15. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3:1526-33. doi: 10.2215/CJN.00950208
  16. Pranata R, Supriyadi R, Huang I, et al. The association between chronic kidney disease and new onset renal replacement therapy on the outcome of COVID-19 patients: a meta-analysis. Clin Med Insights Circ Respir Pulm Med. 2020;14:1179548420959165. doi: 10.1177/1179548420959165
  17. Tadic M, Cuspidi C, Grassi G, Mancia GM. COVID‐19 and arterial hypertension: Hypothesis or evidence? J Clin Hypertens. 2020;22(7):1120-6. doi: 10.1111/jch.13925
  18. Zuin M, Rigatelli G, Zuliani G, et al. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis. J Infect. 2020;81(1):e84-6. doi: 10.1016/j.jinf.2020.03.059
  19. Roncon L, Zuin M, Zuliani G, Rigatelli G. Patients with arterial hypertension and COVID-19 are at higher risk of ICU admission. Br J Anaesth. 2020;125(2):e254-5. doi: 10.1016/j.bja.2020.04.056

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies